ERBB2 and breast cancer: Similarly, afatinib is an irreversible inhibitor of EGFR and HER2, with preliminary evidence of activity in the phase II non-CNS metastatic setting, which is currently in clinical trials for the treatment of breast cancer brain metastases [52].